Association Between Quality of Life and Viral Load Among People With HIV in the Current Antiretroviral Era

Introduction

- •In 2005, first generic ARV treatments were discovered, initiating the new ART era.
- •Quality of life (QoL) is deemed the 4th goal in the UNAIDS HIV/AIDS treatment and control program.
- •Viral load (VL) has the most importance use of monitoring the effectiveness of ART treatment.
- •HIV program economic evaluation has relied on CD4 count benchmarks and their relevant utility scores (Table 1).
- •Whether or not VL is associated with quality of life, enabling the generation of utility scores for relevant economic evaluation is unknown.

Health state	Duration ^h	Utility v
Chronic HIV by CD4+ category ⁴⁰	Per cycle spent in category	
> 500		0.870
351–500		0.860
201–350		0.860
101–200		0.850
51–100		0.850
< 50		0.832

Table 1. Conventional utility scores for CD4 count as parameter input for economic evaluation of HIV care programs

Study objective

•To determine the association between QoL and VL through systematic review

Methods

- •In January 2023, we conducted target searches on PubMed, PsyInfo and Embase for publications in English between 2000 and 2022.
- •Articles were selected for final review if they provided results from assessments of the association between QoL and VL along with other eligibility criteria.
- •SS and VN independently abstracted data and resolved debates by consensus.
- •Population, Intervention (if any), Comparison (if any), and Outcomes framework was used to abstract the studies.
- •Findings on the associations between QoL and VL were documented.
- •We followed Herzog et al. 2013 to assess study quality. Abstract number: CO124. Board number: 1013

Results




Figure 3. Characteristics of studies using MOS-HIV measure

Author Year	N, Country	Association Results	VL Measure	Population Setting	Age	Gender
					18–25: 157	Male: 393
	N=602	Showed association between QoL and	VL< 20 copies/ml (undetectable) and		26–50: 247	Female: 189
A. Ahmed 2021	Pakistan	detectable VL	≥ 20 copies/ml (detectable)	Hospital	> 50: 198	Transgender: 20
	N=1480	Showed association between QoL and	VL< 50 copies/ml (undetectable) and			Male 958
R. Castro 2019	Brazil	VL	≥ 50 copies/ml (detectable)	Specific clinic	Median: 43.1	Female 522
C. Chapman	N=335	Showed NO association between QoL	<10,000 copies/mL or >10,000			Female: 68
	US	and VL	copies/mL	Multiple clinics	Avg: 37.6	Male:267
	N=368	Showed association between QoL and	I VL (>50,000,5001–50,000, or ≤ 5000			Female: 7
V. R. Joyce 2009	US, UK, Canada	VL	copies/mL)	Existing study patients	Avg: 47.51	Male: 361
	N=250	Showed association between QoL and	I			Female: 44
	Germany	VL in multivariable models	Mean VL: 34234 ± 98438 copies/ml	Unclear	Avg: 40.4	Male: 206
					≥18	
	N=943	Showed NO association between QoL	VL< 20 copies/ml (undetectable) \ge 20		Avg: 50.9	Female: 322
A. Venturini 2017	Italy	and VL	copies/ml (detectable)	Specific clinic	Range: 21 - 86	Male: 621
					Avg: 39.8	
	N=250	Showed PHS score asscociated with	VL <30,000 copies/ml vs > 30,000		Median: 38.8	Female: 35
T. Delate 2001	US	VL	copies/ml	Specific clinic	Rnge: 21.8 - 69.8	Male: 207
	N=800	Showed association between QoL and	VL <50 copies/ml (undetectable) and			Female: 592
E. Osati 2020	Tanzania	VL	≥ 50 copies/ml (detectable)	Specific clinic	Range: 30 - 59	Male: 208

Figure 4. Characteristics of studies using EQ-5D measure

value

Van Nghiem, PhD¹, Shelita Smith, MPH¹, Ellen Eaton, MD², Aadia Rana, MD² ¹Department of Health Policy and Organization, ²Department of Medicine, Division of Infectious Diseases

easure	Population Setting	Age	Gender
ml = virologically	Hospital	≤35 and 35+	Female: 222 Male: 107 Unknown: 1
undetectable	Hospital	Avg: 45.8	Female:50 Male: 187
ml and ≥ 40	Clinical trial within a clinic	Range: 20 - 70	Female: 160 Male: 361
01–50,000, or ≤ .)	Existing study patients, though not clinical	Avg: 47.51	Female: 7 Male: 361
ies/ml or ml	General population	Range: 15 - 45+	All women
na VL	Clinical trial	Avg: 39.9 18+	Female: 28 Male: 240
nts of number of , 40,000,	Clinical trial	≥18	Female: 739 Male: 824
ies/ml vs. ≤)	2 clinics	≥18	Female: 710 Male: 237
nl as detectable	Hospital	Median: 43 Range: 37 - 49	Female: 91 Male: 111
nt of copies/mL	Clinical trial	Avg: 37.46 Range: 19 - 78	Female: 189 Male: 923
anification of	General population	≥16 Avg: 40 Median: 38 Range: 20-76	Female: 134 Male: 263
l of <30,000 s > 30,000	Specific clinic	Avg: 39.8 Median: 38.8 Range: 21.8 - 69.8	Female: 35 Male: 207

sample of studies. association. VL.

1. Belay et al. 2021. Cost-utility analysis of Dolutegravir- versus Efavirenz-based regimens as a first-line treatment in adults with HIV/AIDS. *PharmacoEconomics-Open*. 2. Herzog et al. 2013. Is healthcare workers' intention to vaccinate related to their knowledge, beliefs, and attitudes? A systematic review. BMC Public Health.



Results

•A total of 65 studies on 26,329 people living with HIV were selected for full-text review.

•Each study had 24 - 1,668 people living with HIV. The largest study was composed of U.S. military personnel.

•Another 16 studies satisfied all eligibility criteria except reporting the findings on the association between QoL and VL. Thus, they were not included in the final

•Studies were conducted on a wide geographic coverage across the globe.

•Among 65 studies: Sixty percent (39/65) of these articles reported a statistically significant association between QoL (or some subscales of the QoL measure) and VL while the remaining 26 articles reported no Another 16 (16/81) articles were inconclusive about the association between QoL and

•One of the greatest challenges in studying QoL among people living with HIV is loss to follow up.

•There was a wide range of benchmarks to measure VL.

Conclusion

•Per QoL measure, there have been not so many studies. •Conventionally, studies using EQ-5D have the highest potential to derive utility scores.

•Also, heterogeneity in VL definitions currently impedes the immediate next steps to derive standard utility measures based on QoL measure an VL assessment.

•More data and harmonization of data will be needed to facilitate an estimation of utility scores relevant to VL.

References

Acknowledgment: Research for this project was supported by the Center for AIDS Research at the University of Alabama at Birmingham (NIH P30AI027767) and the CHERISH program at Cornell University (NIH U24DA057650).